Report overview
Recombinant human erythropoietin injection (CHO cells) is clinically used for anemia caused by renal insufficiency, including hemodialysis, peritoneal dialysis and non dialysis patients with chronic renal failure.
This report contains market size and forecasts of Recombinant Human Erythropoietin Injection in global, including the following market information:
Global Recombinant Human Erythropoietin Injection Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Recombinant Human Erythropoietin Injection Market Sales, 2018-2023, 2023-2030, (K Units)
Global top five Recombinant Human Erythropoietin Injection companies in 2022 (%)
The global Recombinant Human Erythropoietin Injection market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
0.3ml Branch Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Recombinant Human Erythropoietin Injection include Roche, LG Chem, Kexing Biopharm, 3SBio Group, Harbin Pharmaceutical Group Holding, Dong-E-E-Jiao, Humanwell Healthcare, Ncpc Genetech Biotechnology and Shandong E-hua Biotech Pharmaceutical, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Recombinant Human Erythropoietin Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Human Erythropoietin Injection Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Recombinant Human Erythropoietin Injection Market Segment Percentages, by Type, 2022 (%)
0.3ml Branch
0.6ml Branch
1ml Branch
Others
Global Recombinant Human Erythropoietin Injection Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Recombinant Human Erythropoietin Injection Market Segment Percentages, by Application, 2022 (%)
Renal Failure Anemia
Non Renal Anemia
Global Recombinant Human Erythropoietin Injection Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Recombinant Human Erythropoietin Injection Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Human Erythropoietin Injection revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Human Erythropoietin Injection revenues share in global market, 2022 (%)
Key companies Recombinant Human Erythropoietin Injection sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Recombinant Human Erythropoietin Injection sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
LG Chem
Kexing Biopharm
3SBio Group
Harbin Pharmaceutical Group Holding
Dong-E-E-Jiao
Humanwell Healthcare
Ncpc Genetech Biotechnology
Shandong E-hua Biotech Pharmaceutical
Intas Pharmaceuticals
PeproTech
WELLONA PHARMA
SI HUAN SHENG WU
Shanxi Weiqidaguangming Pharmaceutical
